Abstract:
The most serious COVID-19 side effects brought on by SARS-CoV-2
infection is hypercoagulopathy-induced ischemia damage to important organs, which
frequently results in COVID-19 infection-related impairment and death in patients.
Therefore, it is possible to lower the above-mentioned indicators of morbidity and
mortality by carefully examining the factors that contribute to hypercoagulopathy,
selecting patients who are predisposed to the emergence of this pathological process,
and performing specialized proliferative and therapeutic procedures for them. The
MTR gene polymorphisms, which are thrombophilic genes and one of the causes of
hypercoagulopathy, have been studied in COVID-19-infected Uzbek patients to better
understand the relationship between the alleles of these genes and the amount of
homocysteine in these patients as well as the role they may play in the pathogenesis of
COVID-19.
